ARGS– Article Below
NOTE***** OPMZ is an MMJ tech company with disruptive tech in the medical cannabis field and on high alert today as momentum is building!
Up over 30% and just getting started
As this week progresses we believe the BUZZ and momentum around OPMZ will definitely continue.
***Get our small cap profiles, special situation and watch alerts in real time. We are now offering our
VIP SMS/text alert service for free, simply text the word “Alerts” to the phone number 25827 from your
Argos Therapeutics Inc (NASDAQ:ARGS) had its target price reduced by Stifel Nicolaus from $16.00 to $10.00 in a research report issued on Wednesday,Market Beat.com reports. The firm currently has a “buy” rating on the biopharmaceutical company’s stock. Stifel Nicolaus’ price target points to a potential upside of 47.28% from the company’s previous close.
Shares of Argos Therapeutics (NASDAQ:ARGS) opened at 6.79 on Wednesday. The firm’s market cap is $140.79 million. Argos Therapeutics has a 52 week low of $1.61 and a 52 week high of $9.64. The firm’s 50-day moving average price is $4.93 and its 200 day moving average price is $4.25.
Argos Therapeutics (NASDAQ:ARGS) last posted its quarterly earnings results on Tuesday, March 29th. The biopharmaceutical company reported ($0.84) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.88) by $0.04. Equities analysts anticipate that Argos Therapeutics will post ($3.58) EPS for the current year.
Several other research firms also recently commented on ARGS. Zacks Investment Research raised shares of Argos Therapeutics from a “hold” rating to a “buy” rating and set a $3.00 target price on the stock in a research report on Thursday, January 28th. FBR & Co. reissued a “buy” rating on shares of Argos Therapeutics in a research report on Saturday, March 19th. Piper Jaffray reissued a “buy” rating and set a $11.00 target price on shares of Argos Therapeutics in a research report on Monday, March 7th. Needham & Company LLC lowered their target price on shares of Argos Therapeutics from $14.00 to $11.00 and set a “buy” rating on the stock in a research report on Tuesday, March 8th. Finally, JMP Securities lowered their target price on shares of Argos Therapeutics from $17.00 to $12.00 and set a “market outperform” rating on the stock in a research report on Wednesday, March 9th. One analyst has rated the stock with a hold rating and eight have given a buy rating to the company’s stock. Argos Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $11.89.
Argos Therapeutics, Inc (NASDAQ:ARGS) is a biopharmaceutical company focused on the development and commercialization of personalized immunotherapies for the treatment of cancer and infectious diseases based on its technology platform called Arcelis.
Source: American Banking and Market News
SCS LLC has not been compensated for this article.
SCS LLC was previously compensated up to twenty thousand dollars each by star media llc for the mention of INVT and XXII however those contracts have expired.